Mangrove Partners Mereo Biopharma Group PLC Call Options Transaction History
Mangrove Partners
- $890 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MREO
# of Institutions
86Shares Held
102MCall Options Held
121KPut Options Held
208K-
Rubric Capital Management LP New York, NY15.3MShares$62.8 Million1.63% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.8MShares$48.3 Million0.08% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.28MShares$38.1 Million1.04% of portfolio
-
Janus Henderson Group PLC London, X07.88MShares$32.3 Million0.02% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$27.5 Million0.51% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $512M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...